· Published by Health Canada · Official notice
This is duplicated text of a letter from Guidant Canada Corporation.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
January 21, 2006
Subject: Two subsets of PULSAR® MAX, PULSAR, DISCOVERY®, MERIDIAN®, PULSAR MAX II, DISCOVERY II, VIRTUS® Plus II, INTELIS® II and CONTAK® TR implantable pacemakers
Dear Health Care Professional,
This letter is intended to inform you of important safety information regarding the potential for loss of therapy due to hermetic seal degradation in two subsets of PULSAR MAX, PULSAR, DISCOVERY, MERIDIAN, PULSAR MAX II, DISCOVERY II, VIRTUS Plus II, INTELIS II and CONTAK TR pacemakers. This letter advises physicians about potential unanticipated device behaviors and is intended to limit adverse events.
Guidant previously communicated information regarding hermetic seal degradation in a subset of the above pacemakers in a physician letter dated July 18, 2005. Since that time, the projected rate of occurrence has increased for this advisory population. In addition, Guidant has identified a second population of devices outside of the advisory population that may also be susceptible to hermetic seal degradation. Our records indicate that you have implanted or are monitoring patients with devices from one or both of these populations. Health Canada classified the July 18, 2005 physician letter as a Priority I recall and has indicated this communication may be classified as an expansion of that recall.
As described in the July 18, 2005 letter to physicians, Guidant's Quality System determined that a hermetic sealing component utilized in 78,000 devices manufactured between November 25, 1997 and October 26, 2000 may experience a gradual degradation, resulting in a higher than normal moisture content within the pacemaker case late in the device's service life. This may lead to one or more of the following device behaviors:
Important Clinical Notes:
Observed rate of occurrence:* Guidant has further defined the advisory population as 77,500 devices manufactured between October 27, 1997 and October 26, 2000. Since the July 18, 2005 physician letter, Guidant has identified 76 additional devices that may have exhibited hermetic seal degradation. Seventy-one (71) of those devices have been confirmed through laboratory analysis to have exhibited hermetic seal degradation; two devices are currently undergoing analysis; three devices may have experienced hermetic seal degradation but were not returned to Guidant for confirmation. A total of 145 reported incidents out of 77,500 devices represents a rate of occurrence of 0.19%. It is estimated that 16,000 devices in this population remain implanted worldwide and an estimated 800 devices remain implanted in Canada.
Clinical Implications: As of January 9, 2006, Guidant has confirmed a total of 71 reports of loss of pacing output, including ten patients who experienced syncope and two instances of cardiac arrest with resuscitation. Loss of pacing output has also been associated with reports of presyncope requiring hospitalization. Guidant has received 65 reports of Maximum Sensor Rate (MSR) pacing associated with hermetic seal degradation. Sustained MSR pacing has been associated with one report of myocardial infarction, two reports of possible development of heart failure, and five reports of shortness of breath that could be indicative of heart failure. As reported in the July 18, 2005 physician letter, one patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later expired. It is unknown if the device experienced hermetic seal degradation as the device was not returned and hermetic seal degradation could not be confirmed.
Projected rate of occurrence:† Based on further investigation and laboratory analysis of returned devices, Guidant's projected rate of occurrence for reported events within the remaining lifetime of active devices is now estimated to be between 0.31% and 0.88%, which has increased from the July 18, 2005 estimate of between 0.17% and 0.51%.
Since our July 18, 2005 physician letter, Guidant has identified a second population of 54,000 devices manufactured between October 19, 1998 and December 5, 2000 that are at risk of hermetic seal degradation, though at a much lower rate than the advisory population. Guidant identified this second population after investigating reports of five pacemakers outside the advisory population exhibiting clinical behaviors similar to those described in the July 18, 2005 physician letter. At the time devices in the second population were assembled, hermetic sealing components susceptible to gradual degradation were mistakenly mixed with a much larger group of non-susceptible components. Within the second population of 54,000 devices, Guidant has identified by model number and date-of-manufacture approximately 2,500 devices with susceptible components, but is unable to identify susceptible devices by serial number.
Observed rate of occurrence:* As of January 9, 2006, two devices in the second population have been confirmed to have exhibited hermetic seal degradation; three devices may have exhibited hermetic seal degradation but have not been returned to Guidant for confirmation. A total of five reported incidents out of 54,000 represents a rate of occurrence of 0.009%. It is estimated that 19,300 devices in this second population remain implanted worldwide.
Clinical Implications: As of January 9, 2006, Guidant has confirmed two reports of loss of pacing output, including one patient who required hospitalization for presyncope and chest pain. Three devices exhibited high rate MSR pacing and remain implanted.
Projected rate of occurrence:† If a device in the second population has a susceptible component, it is subject to a risk of hermetic seal degradation equal to that of the original population. However, because devices with a susceptible component cannot be specifically identified and are distributed among the 54,000 devices in the second population, the projected rate of occurrence for reported events within the second population is substantially lower than the projected rate of occurrence for the original advisory population. For the remaining lifetime of active devices, the projected rate of occurrence for reported events within the second population is estimated to be between 0.02% and 0.06%.
* The number of actual clinical incidents may be greater than the number reported to Guidant.
† Assumes that devices remain implanted through normal replacement indicators. Predictive modeling is inherently uncertain due to its dependence on the device age distribution of reported events and resultant statistical approximations and assumptions.
Original advisory population
Guidant's original patient management recommendations from the July 18, 2005 physician letter remain unchanged. When determining the most appropriate patient management option, physician should consider the unique needs of each individual patient, including pacemaker dependency, as well as the age and remaining service life of the pacemaker. Guidant recommends that physicians reassess their patients in light of the increased projected rate of occurrence.
| Accelerometer Status | Evaluation Criteria |
|---|---|
| ON |
|
| OFF | Temporarily program the accelerometer ON and evaluate as described above. |
Second/New Population
Physicians should consider the above recommendations while taking into account the lower projected rate of occurrence and the unique needs of each individual patient, including pacemaker dependency, when making patient management decisions for patients in the second population.
Guidant's warranty supplement program, subject to certain conditions, provides a no cost replacement device. The program is available through June 30, 2006 and is applicable to both populations.
Both populations include the following model numbers:
| Device Family | Model | Device Family | Model |
|---|---|---|---|
| * Devices not sold in Canada | |||
| DISCOVERY II | 0481, 0981, 1184, 1186, 1187, 1283, 1284, 1285, 1286 | PULSAR MAX | 1170, 1171, 1270 |
| DISCOVERY | 1174, 1175, 1273, 1274, 1275 | PULSAR MAX II | 1180, 1181, 1280 |
| PULSAR | 0470, 0870, 0970, 0972, 1172, 1272 | MERIDIAN | 0476, 0976, 1176, 1276 |
| INTELIS II* | 1483, 1484, 1485, 1384, 1385, 1349, 1499 | CONTAK TR | 1241 |
| VIRTUS Plus II* | 1380, 1480 | ||
A list of second population devices specific to your clinic is enclosed. A device model/serial number look-up/search tool is also available at http://www.guidant.com in the Product Safety Information section.
Guidant recognizes the impact of this communication on both you and your patients, and wants to reassure you that patient safety remains Guidant's primary concern. As always, if you have any questions regarding this communication, please contact your local Guidant representative or Guidant Technical Services at 1.800.CARDIAC (227-3422).
Guidant Canada
505 Apple Creek Blvd., Unit 4
Markham, Ontario L3R 5B1
CANADA
Phone: (905) 947-5800 or 1-800-268-4487
Fax: (905) 947-5830
Any suspected adverse incident can also be reported to:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
The Medical Devices Problem Report Form and Guidelines can be found on the Health Canada web site.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
Sincerely,
original signed by
Scott Kadwell
Country Manager, Cardiac Rhythm Management
Guidant Canada Corporation
Communication Summary
| Population | Advisory Population | Advisory Population - Updated | Second Population |
|---|---|---|---|
| * Predictive modeling is inherently uncertain, and assumes that the devices remain implanted throughout normal replacement indicators. | |||
| ** In one report, a patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later expired. It is unknown if the device experienced hermetic seal degradation as the device was not returned and hermetic seal degradation could not be confirmed. | |||
| Communication Method | Physician Letter | Physician Letter | |
| Date | July 18, 2005 | January 20, 2006 | |
| Affected Population | A bounded subset manufactured between October 27, 1997 and October 26, 2000 | A bounded subset manufactured between October 19, 1998 and December 5, 2000 | |
| Worldwide Devices Distributed | 78,000 | 77,500 | 54,000 |
| Remaining Implanted Devices in the US (approximate) | 18,000 | 10,800 | 11,700 |
| Cumulative Reported Incidents | 69 | 145 | 5 |
| Reported Incidence Rate | 0.09% | 0.19% | 0.009% |
| Projected Incidence Rate* | 0.17% to 0.51% | 0.31% to 0.88% | 0.02% to 0.06% |
| Cumulative Reported Deaths** | 0 | 0 | 0 |
| Root Cause | A hermetic sealing component may experience gradual degradation, resulting in a higher than normal moisture content within the pacemaker case late in the device's service life. This may lead to one or more inappropriate behaviors, exhibited individually or in combination. | ||
| Health Canada Classification | Priority I recall | Priority I recall | Health Canada has indicated this communication may be classified as an expansion of the July 2005 Priority I recall. |
| Warranty Supplement Program | Effective through 06/30/2006 | Effective through 06/30/2006 | Effective through 06/30/2006 |
| Recommendations | See physician communication July 18, 2005 | Unchanged. Additionally Guidant recommends that physicians reassess their patients in light of the increased projected rate of occurrence. | Physicians should consider the July 2005 communication recommendations while taking into account the lower projected rate of occurrence and the unique needs of each individual patient, including pacemaker dependency, when making patient management decisions. |
Fax-back Confirmation Form
| Device Family | Model | Device Family | Model |
|---|---|---|---|
| * Devices not sold in Canada | |||
| DISCOVERY II | 0481, 0981, 1184, 1186, 1187, 1283, 1284, 1285, 1286 | PULSAR MAX | 1170, 1171, 1270 |
| DISCOVERY | 1174, 1175, 1273, 1274, 1275 | PULSAR MAX II | 1180, 1181, 1280 |
| PULSAR | 0470, 0870, 0970, 0972, 1172, 1272 | MERIDIAN | 0476, 0976, 1176, 1276 |
| INTELIS II* | 1483, 1484, 1485, 1384, 1385, 1349, 1499 | CONTAK TR | 1241 |
| VIRTUS Plus II* | 1380, 1480 | ||
Please complete this form and return to:
Guidant Canada Regulatory
Fax: 1-800-390-3043
Institution:
Address:
City:
Province:
Postal Code:
This will confirm receipt of the Urgent Medical Device Safety Information Notice dated January 21, 2006 on the above-mentioned PULSAR® MAX, PULSAR, DISCOVERY®, MERIDIAN®, PULSAR MAX II, DISCOVERY II, VIRTUS® Plus II, INTELIS® II, AND CONTAK® TR
Signed:
Date:
Name:(Please print or type)
Title:(Please print or type)
Department:
Telephone:
Fax:
Internal Use Only
Confirmed by
Date